OBJECTIVE: The purpose of this study was to examine the proportion of men who died from prostate cancer (PrCa) vs. with PrCa and assess the comorbid conditions associated with other-cause deaths. STUDY DESIGN AND SETTING: We identified all male decedents aged >/=65 years in Jefferson County, AL, in 1993-1995. By crosslinking three databases (death certificate, Medicare, and Veteran's Administration), we identified men whose deaths might have been caused by PrCa. We abstracted and reviewed medical records to rate comorbid conditions and determine whether or not death was due to PrCa. RESULTS: Of 561 men with a premortem diagnosis of PrCa, 42% died from PrCa and 53% died with PrCA; 50.2% of blacks died from PrCa vs. 36.9% of Whites. Other factors related to dying with PrCa included older age at death and a serious, or very serious, comorbid condition. Treatment did not have an independent effect on cause of death (i.e., death with vs. from PrCa). CONCLUSIONS: Comorbidity was an independent predictor of dying with PrCa, even after adjustment for ethnicity, age, and treatment. Given the as yet unproven benefit of PrCa screening, our results extend the body of information relevant to the screening decision; among men dying with a diagnosis of PrCa, only about 1/3 to 1/2 died from the disease.
OBJECTIVE: The purpose of this study was to examine the proportion of men who died from prostate cancer (PrCa) vs. with PrCa and assess the comorbid conditions associated with other-cause deaths. STUDY DESIGN AND SETTING: We identified all male decedents aged >/=65 years in Jefferson County, AL, in 1993-1995. By crosslinking three databases (death certificate, Medicare, and Veteran's Administration), we identified men whose deaths might have been caused by PrCa. We abstracted and reviewed medical records to rate comorbid conditions and determine whether or not death was due to PrCa. RESULTS: Of 561 men with a premortem diagnosis of PrCa, 42% died from PrCa and 53% died with PrCA; 50.2% of blacks died from PrCa vs. 36.9% of Whites. Other factors related to dying with PrCa included older age at death and a serious, or very serious, comorbid condition. Treatment did not have an independent effect on cause of death (i.e., death with vs. from PrCa). CONCLUSIONS: Comorbidity was an independent predictor of dying with PrCa, even after adjustment for ethnicity, age, and treatment. Given the as yet unproven benefit of PrCa screening, our results extend the body of information relevant to the screening decision; among men dying with a diagnosis of PrCa, only about 1/3 to 1/2 died from the disease.
Authors: Mallory G Cases; Andrew D Frugé; Jennifer F De Los Santos; Julie L Locher; Alan B Cantor; Kerry P Smith; Tony A Glover; Harvey J Cohen; Michael Daniel; Casey D Morrow; Douglas R Moellering; Wendy Demark-Wahnefried Journal: Contemp Clin Trials Date: 2016-08-23 Impact factor: 2.226
Authors: Mary Putt; Judith A Long; Chantal Montagnet; Jeffrey H Silber; Virginia W Chang; J Sanford Schwartz; Craig Evan Pollack; Yu-Ning Wong; Katrina Armstrong Journal: Med Care Res Rev Date: 2009-04-08 Impact factor: 3.929
Authors: Sarathi Kalra; Spyridon Basourakos; Angela Abouassi; Mary Achim; Robert J Volk; Karen E Hoffman; John W Davis; Jeri Kim Journal: Nat Rev Urol Date: 2016-03-22 Impact factor: 14.432
Authors: Lisa M Lowenstein; Spyridon P Basourakos; Michelle D Williams; Patricia Troncoso; Justin R Gregg; Timothy C Thompson; Jeri Kim Journal: Nat Rev Clin Oncol Date: 2019-03 Impact factor: 66.675
Authors: Ashley Wilder Smith; Bryce B Reeve; Keith M Bellizzi; Linda C Harlan; Carrie N Klabunde; Marni Amsellem; Arlene S Bierman; Ron D Hays Journal: Health Care Financ Rev Date: 2008